Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA R ALLEGRETTI

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1992932453
CMS profile
1103576
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$151,827.91

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $55,968.86 37
Janssen Biotech, Inc. $33,294.78 27
Ferring Pharmaceuticals Inc. $21,922.05 17
E.R. Squibb & Sons, L.L.C. $16,301.42 10
PFIZER INC. $11,890.00 4
Janssen Global Services, LLC $3,515.00 1
GlaxoSmithKline, LLC. $2,800.00 2
Ferring Pharmaceuticals AS $2,700.00 1
Janssen Research & Development, LLC $1,240.00 2
Celgene Corporation $1,181.72 2
Merck Sharp & Dohme LLC $1,000.00 1
AIMMUNE THERAPEUTICS, INC. $14.08 1

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA R ALLEGRETTI

NPI 1992932453 · CMS profile ID 1103576

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992932453?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992932453?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992932453?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1992932453?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $151,827.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $1,300.0002/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998204457 CMS
ABBVIE INC. $114.3001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998204453 CMS
ABBVIE INC. $364.3101/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998204455 CMS
ABBVIE INC. $1,950.0001/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998204451 CMS
ABBVIE INC. $134.0001/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998204449 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,823.40 66
PY2020 $26,988.36 26
PY2021 $43,165.64 29
PY2022 $100,300.81 79
PY2023 $151,827.91 105
PY2024 $125,776.18 80
PY2025 $201,022.99 113

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,648.70 15
PY2025 Principal investigator $285,274.70 49
PY2024 Recipient $14,903.08 15
PY2024 Principal investigator $367,846.08 28
PY2023 Recipient $3,330.00 5
PY2023 Principal investigator $325,059.58 21
PY2022 Recipient $9,250.00 8
PY2022 Principal investigator $397,246.35 26
PY2021 Recipient $14,750.00 11
PY2021 Principal investigator $440,686.24 35
PY2020 Recipient $10,510.00 6
PY2020 Principal investigator $254,489.94 31
PY2019 Principal investigator $545,453.77 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $1,337.00 12/19/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541920
Principal investigator 1 Eli Lilly and Company $388.40 12/08/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187872797
Recipient F. Hoffmann-La Roche AG $157.91 12/02/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536614
Recipient F. Hoffmann-La Roche AG $234.69 12/02/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536627
Principal investigator 1 Genentech, Inc. $1,658.00 11/25/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541998
Principal investigator 1 SANOFI US SERVICES INC. $23,694.00 11/21/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226147158
Principal investigator 1 SANOFI US SERVICES INC. $472.00 11/12/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226147151
Principal investigator 1 SANOFI US SERVICES INC. $21,659.00 11/12/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1226147154
Recipient F. Hoffmann-La Roche AG $163.94 11/10/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536607
Recipient F. Hoffmann-La Roche AG $241.30 11/10/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536618
Principal investigator 1 Genentech, Inc. $1,419.00 11/07/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211542002
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,478.31 10/10/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223264460
Principal investigator 1 ABBVIE INC. $14,899.95 10/09/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202406943
Recipient F. Hoffmann-La Roche AG $454.82 10/06/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536602
Recipient F. Hoffmann-La Roche AG $896.83 10/05/2025 Covered Recipient Physician A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536621
Principal investigator 1 Genentech, Inc. $1,342.00 10/03/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541990
Principal investigator 1 F. Hoffmann-La Roche AG $1,337.00 09/23/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541916
Principal investigator 1 F. Hoffmann-La Roche AG $12,304.00 09/04/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541912
Principal investigator 1 Genentech, Inc. $1,219.14 09/03/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541966
Principal investigator 1 Ferring Pharmaceuticals AS $850.00 08/27/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242059743
Principal investigator 1 F. Hoffmann-La Roche AG $1,640.00 08/26/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541907
Principal investigator 1 Genentech, Inc. $1,219.14 08/21/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541973
Principal investigator 1 F. Hoffmann-La Roche AG $3,766.00 08/07/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541891
Principal investigator 1 F. Hoffmann-La Roche AG $10,000.00 07/31/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541887
Principal investigator 1 F. Hoffmann-La Roche AG $7,852.00 07/31/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541895
Principal investigator 1 F. Hoffmann-La Roche AG $10,089.00 07/31/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541899
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 07/31/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211541903
Principal investigator 1 Genentech, Inc. $1,649.70 07/16/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541970
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/07/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
Prospective evaluation of ustekinumab dose intesification in inflammatory bowel diseases No dispute reported 06/30/2026 1175303636
Principal investigator 1 Genentech, Inc. $2,074.00 06/19/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541940
Principal investigator 1 Ferring Pharmaceuticals AS $2,700.00 06/13/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242059730
Principal investigator 1 Ferring Pharmaceuticals AS $250.00 06/13/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242059734
Principal investigator 1 Ferring Pharmaceuticals AS $4,225.00 06/13/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242059740
Principal investigator 1 Ferring Pharmaceuticals AS $17,787.00 06/05/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis No dispute reported 06/30/2026 1242059722
Principal investigator 1 Ferring Pharmaceuticals AS $2,700.00 06/05/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis No dispute reported 06/30/2026 1242059724
Principal investigator 1 Genentech, Inc. $4,087.98 05/21/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541959
Principal investigator 1 Genentech, Inc. $2,379.00 05/15/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541947
Principal investigator 1 Genentech, Inc. $2,174.00 05/08/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541950
Recipient F. Hoffmann-La Roche AG $328.79 05/05/2025 Covered Recipient Physician RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis – Findings from the phase 2b TUSCANY-2 trial No dispute reported 06/30/2026 1211536623
Recipient F. Hoffmann-La Roche AG $153.24 05/03/2025 Covered Recipient Physician Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis – Results from TUSCANY-2 No dispute reported 06/30/2026 1211536575
Recipient F. Hoffmann-La Roche AG $181.85 05/03/2025 Covered Recipient Physician RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis – Findings from the phase 2b TUSCANY-2 trial No dispute reported 06/30/2026 1211536578
Recipient F. Hoffmann-La Roche AG $387.08 05/03/2025 Covered Recipient Physician Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis – Results from TUSCANY-2 No dispute reported 06/30/2026 1211536610
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.89 04/25/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223264440
Principal investigator 1 Genentech, Inc. $2,600.91 04/17/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541963
Recipient F. Hoffmann-La Roche AG $103.57 04/14/2025 Covered Recipient Physician TUSCANY-2: A Dose-Ranging Phase 2b Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-like Ligand 1A (Anti-TL1A) in Adults with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1211536598
Principal investigator 1 Genentech, Inc. $4,758.00 04/08/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541955
Principal investigator 1 Celgene Corporation $2,000.00 04/01/2025 Non-covered Recipient Entity
Brigham And Womens Physicians Organization
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222307207
Recipient F. Hoffmann-La Roche AG $378.19 03/31/2025 Covered Recipient Physician A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536582
Recipient F. Hoffmann-La Roche AG $176.66 03/31/2025 Covered Recipient Physician A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536585
Recipient F. Hoffmann-La Roche AG $148.88 03/31/2025 Covered Recipient Physician A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536590
Recipient F. Hoffmann-La Roche AG $4,640.95 03/31/2025 Covered Recipient Physician A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1211536594
Principal investigator 1 Janssen Research & Development, LLC $1,242.15 03/31/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
Prospective evaluation of ustekinumab dose intesification in inflammatory bowel diseases No dispute reported 06/30/2026 1175303707
Principal investigator 1 Amgen Inc. $2,500.00 03/22/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1246637376
Principal investigator 1 Celgene Corporation $2,000.00 03/04/2025 Non-covered Recipient Entity
Brigham And Womens Physicians Organization
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222307159
Principal investigator 1 Celgene Corporation $2,000.00 02/20/2025 Non-covered Recipient Entity
Brigham And Womens Physicians Organization
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222307221
Principal investigator 1 Ferring Pharmaceuticals AS $2,700.00 02/13/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis No dispute reported 06/30/2026 1242059712
Principal investigator 1 Ferring Pharmaceuticals AS $17,787.00 02/13/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis No dispute reported 06/30/2026 1242059717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,500.00 02/12/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223264424
Principal investigator 1 Genentech, Inc. $1,500.00 02/05/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541932
Principal investigator 1 Genentech, Inc. $7,852.00 02/05/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541936
Principal investigator 1 Genentech, Inc. $10,000.00 02/05/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211541943
Principal investigator 1 Genentech, Inc. $2,365.74 01/14/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
RVT-3101-201 (TAHOE) No dispute reported 06/30/2026 1211541923
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,746.39 01/03/2025 Covered Recipient Teaching Hospital
Brigham And Womens Hospital
An Observational Study in Adults with Clostridioides difficile Infection to Determine the Feasibility and Logistics of Biospecimen Collection Transportation and Testing at Select US Study Sites No dispute reported 06/30/2026 1185543356
Principal investigator 1 Ferring Pharmaceuticals AS $425.00 01/03/2025 Covered Recipient Teaching Hospital
BRIGHAM AND WOMENS HOSPITAL
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242059708